Drug
Ripretinib
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Group | Multi-target TKI |
| Mechanism of Action | KIT/PDGFR inhibitor |
| Half-life | 13–15 h |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing via VEGFR/PDGFR and RAS–MEK–ERK/PI3K–AKT blockade, vascular normalization, and S-phase depletion (Viktorsson et al., Strahlentherapie und Onkologie, 2023; Affolter et al., Head & Neck, 2017; Shen et al., European Journal of Medical Research, 2026). Because the antiangiogenic and DNA-repair effects are not tumor-restricted, a theoretical increase in normal-tissue adverse events is plausible—chiefly vascular/ischemic injury and impaired healing in irradiated tissue, with the bowel and other visceral organs the principal concern.
Data on this page refer exclusively to patients treated with
Ripretinib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Multi-target TKI group page.